Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes

Kidney International

Volumn 63, Issue 1, 2003, Pages 209-216

  Utimura, Ricardo ^a   Fujihara, Clarice Kazue ^a   Mattar, Ana Lúcia ^a   Malheiros, Denise Maria Avancini Costa ^a   Noronha, Irene De Lourdes ^a   Zatz, Roberto ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Lab Fisiopatol Ren Ave Doutor A ^*  (Brazil)

Author keywords

Albuminuria; Anti inflammatory drugs; Diabetic nephropathy; End stage renal failure; Glomerulosclerosis; Inflammation; Progressive renal disease; Renoprotection

Indexed keywords

CELL ADHESION MOLECULE; ISOPHANE INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; GLOMERULAR DYSFUNCTION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; KIDNEY BLOOD FLOW; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENOVASCULAR HYPERTENSION; UNINEPHRECTOMY;

EID: 0037213082     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00736.x     Document Type: Article

References (46)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Zatz R, Dunn BR, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
3. Young BA, Johnson RJ, Alpers CE, et al: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935-944, 1995
4. Ihm CG, Park JK, Hong SP, et al: A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79:33-37, 1998
5. Cortes P, Zhao X, Riser BL, Narins RG: Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int 51:57-68, 1997
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
7. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
8. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
9. Fujihara CK, Malheiros DM, Donato JL, et al: Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney. Am J Physiol 274:F573-F579, 1998
10. Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54:1510-1519, 1998
11. Romero F, Rodriguez-Iturbe B, Parra G, et al: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955, 1999
12. European Mycophenolate Mofetil Cooperative Study Group: Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 68:391-396, 1999
13. Fujihara CK, Noronha IL, Malheiros DMAC, et al: Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11:283-290, 2000
14. Remuzzi G, Zoja C, Gagliardini E, et al: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542-1549, 1999
15. Steffes MW, Brown DM, Mauer SM: Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes 27:35-41, 1978
16. Anderson S, Rennke HG, Brenner BM: Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 41:891-897, 1992
17. Hirose K, Osterby R, Nozawa M, Gundersen HJ: Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 21:889-895, 1982
18. Harris RC, Haralson MA, Badr KF: Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Lab Invest 66:548-554, 1992
19. Riser BL, Cortes P, Zhao X, et al: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90:1932-1943, 1992
20. Riser BL, Cortes P, Heilig C, et al: Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 148:1915-1923, 1996
21. Suda T, Osajima A, Tamura M, et al: Pressure-induced expression of monocyte chemoattractant protein-1 through activation of MAP kinase. Kidney Int 60:1705-1715, 2001
22. Gruden G, Thomas S, Burt D, et al: Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction. Proc Natl Acad Sci USA 94:12112-12116, 1997
23. Becker BN, Yasuda T, Kondo S, et al: Mechanical stretch/relaxation stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Exp Nephrol 6:57-66, 1998
24. Riser BL, Varani J, Cortes P, et al: Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: A possible new mechanism for glomerulosclerosis. Am J Pathol 158:11-17, 2001
25. Endlich N, Kress KR, Reiser J, et al: Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12:413-422, 2001
26. Petermann AT, Hiromura K, Blonski M, et al: Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 61:40-50, 2002
27. Zatz R: Haemodynamically mediated glomerular injury: The end of a 15-year-old controversy? Curr Opin Nephrol Hypertens 5:468-475, 1996
28. Makita Z, Radoff S, Rayfield EJ, et al: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
29. Doi T, Vlassara H, Kirstein M, et al: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89:2873-2877, 1992
30. Furuta T, Saito T, Ootaka T, et al: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480-485, 1993
31. Sugimoto H, Shikata K, Hirata K, et al: Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: Glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46:2075-2081, 1997
32. Mattana J, Sankaran RT, Singhal PC: Increased applied pressure enhances the uptake of IgG complexes by macrophages. Pathobiology 64:40-45, 1996
33. Lianos EA, Orphanos V, Cattell V, et al: Glomerular expression and cell origin of transforming growth factor-beta 1 in anti-glomerular basement membrane disease. Am J Med Sci 307:1-5, 1994
34. Hibbs JBJ, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157:87-94, 1988
35. Tipping PG, Leong TW, Holdsworth SR: Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest 65:272-279, 1991
36. Sassy-Prigent C, Heudes D, Mandet C, et al: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49:466-475, 2000
37. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al: Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 38:1382-1387, 2001
38. Bilous RW, Mauer SM, Sutherland DE, Steffes MW: Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 38:1142-1147, 1989
39. Eugui EM, Almquist SJ, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 33:161-173, 1991
40. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85-118, 2000
41. Hauser IA, Renders L, Radeke HH, et al: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58-63, 1999
42. Blaheta RA, Leckel K, Wittig B, et al: Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol 6:251-259, 1998
43. Raab M, Daxecker H, Karimi A, et al: In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chim Acta 310:89-98, 2001
44. Hirata K, Shikata K, Matsuda M, et al: Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41:185-192, 1998
45. Senda M, DeLustro B, Eugui E, Natsumeda Y: Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 60:1143-1148, 1995
46. Sugimoto H, Shikata K, Wada J, et al: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42:878-886, 1999